Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus XIFAXAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus XIFAXAN.
CHLOROMYXIN vs XIFAXAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Rifaximin is a non-systemic, gut-selective antibiotic that inhibits bacterial RNA synthesis by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby reducing bacterial overgrowth and altering gut microbiota composition.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
550 mg orally twice daily for traveler's diarrhea; 550 mg orally three times daily for hepatic encephalopathy.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
The terminal elimination half-life for rifaximin after oral administration ranges from 1.8 to 10 hours, with a mean of approximately 6 hours. The half-life is extended in hepatic impairment due to reduced clearance, and no dosage adjustment is recommended for renal impairment.
CHLOROMYXIN is not a recognized drug. No data available.
Rifaximin is primarily eliminated unchanged in feces via biliary excretion (approximately 97% of an oral dose). Renal excretion of unchanged drug accounts for <0.4% of the dose. Fecal elimination is the major route.
Category C
Category C
Antibiotic
Antibiotic